ArticleHereditas2025
Screening and analysis of programmed cell death related genes and targeted drugs in sepsis.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study employed bioinformatics techniques to identify diagnostic genes associated with programmed cell death (PCD) and to explore potential therapeutic agents for the treatment of sepsis.
methodsGene expression profiles from sepsis patients were analyzed to identify differentially expressed genes (DEGs) and hub genes through Weighted Gene Co-expression Network Analysis (WGCNA). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the functions of the DEGs. PCD-related genes were cross-referenced with the identified DEGs. Diagnostic genes were selected using Least Absolute Shrinkage and Selection Operator (LASSO) and Random Forest (RF) methodologies. Single-cell RNA sequencing was utilized to assess gene expression in blood cells, while CIBERSORT was employed to evaluate immune cell infiltration. A transcription factor (TF)-microRNA (miRNA)-hub gene network was constructed, and potential therapeutic compounds were predicted using the Drug Gene Interaction Database (DGIdb). Mendelian Randomization (MR) methods were applied to analyze genome-wide association study (GWAS) data for S100A9, TXN, and GSTO1.
resultsThe analysis revealed 2156 PCD-related genes, 714 DEGs, and 1198 hub genes, with 88 genes enriched in immune and cell death pathways. Five pivotal PCD-related genes (IRAK3, S100A9, TXN, NFATC2, and GSTO1) were identified, leading to the construction of a network comprising six transcription factors and 171 microRNAs. Additionally, seven drugs targeting S100A9, TXN, and NFATC2 were identified. MR analysis suggested that a decrease in GSTO1 levels is associated with an increased risk of sepsis, and that sepsis influences the levels of S100A9, TXN, and GSTO1.
conclusionsThrough bioinformatics approaches, this study successfully identified five genes (IRAK3, S100A9, TXN, NFATC2, and GSTO1) associated with programmed cell death in the context of sepsis. This research identified seven candidate drugs for sepsis treatment and established a methodological framework for predicting biomarkers and drug targets that could be applicable to other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.